Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
WALTHAM - Syndax Pharmaceuticals , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal...